(Q37907518)

25 August 2017

1 reference

title

Fact and fiction in tuberculosis vaccine research: 10 years later (English)

1 reference

25 August 2017

0 references

1 reference

Stefan H E Kaufmann

1

0 references

publication date

1 August 2011

1 reference

Lancet Infectious Diseases

25 August 2017

1 reference

25 August 2017

11

1 reference

25 August 2017

8

1 reference

25 August 2017

633-640

1 reference

Prospects for better tuberculosis vaccines

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The white plague returns to London--with a vengeance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The HIV-associated tuberculosis epidemic--when will we act?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Global tuberculosis drug development pipeline: the need and the reality.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

New vaccines for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Modeling the impact of global tuberculosis control strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Eliminating human tuberculosis in the twenty-first century

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

RUTI: a new chance to shorten the treatment of latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Changing funding patterns in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The potential impact of helminth infection on trials of novel tuberculosis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The quest for biomarkers in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Tuberculosis in Africa: learning from pathogenesis for biomarker identification

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

T-cell quality in memory and protection: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Human gene expression profiles of susceptibility and resistance in tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

A window into third-generation sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Cell-mediated immune responses in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Who puts the tubercle in tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Th1 memory: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

1 reference

7 January 2021

IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

An antimicrobial activity of cytolytic T cells mediated by granulysin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

M. tuberculosis and M. leprae Translocate from the Phagolysosome to the Cytosol in Myeloid Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

CD1: antigen presentation and T cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Central memory and effector memory T cell subsets: function, generation, and maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Regulatory T cells in the control of host-microorganism interactions (*).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Fine-tuning of T cell responses during infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The BCG World Atlas: a database of global BCG vaccination policies and practices

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Tuberculosis vaccines—a new kid on the block

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

The second Geneva Consensus: Recommendations for novel live TB vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Live tuberculosis vaccines based onphoPmutants: a step towards clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Induction of granulysin and perforin cytolytic mediator expression in 10-week-old infants vaccinated with BCG at birth

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

Immunological biomarkers of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970146-3

7 January 2021

10.1016/S1473-3099(11)70146-3

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21798463